知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.022 seconds)

    DIABETES PANEL
    2.
    发明申请
    DIABETES PANEL 审中-公开
    糖尿病面板

    公开(公告)号：US20160299156A1

    公开(公告)日：2016-10-13

    申请号：US15191021

    申请日：2016-06-23

    Applicant: Boston Heart Diagnostics Corporation

    Inventor： Ernst J. Schaefer

    IPC: G01N33/68 ,  G01N33/66 ,  G01N33/74 ,  G01N33/92

    CPC classification number: G01N33/6893 ,  G01N33/66 ,  G01N33/74 ,  G01N33/92 ,  G01N2333/765 ,  G01N2405/02 ,  G01N2800/042 ,  G01N2800/50

    Abstract: The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if said level exceeds a predetermined threshold.

    Abstract translation: 本发明一般涉及预测目前不具有糖尿病的患者发生糖尿病的风险。 本发明可以涉及从糖尿病阴性的患者获得样品，对样品进行测定以获得糖化白蛋白的水平，并且如果所述水平超过预定阈值，则确定发展为糖尿病状况的风险升高。

    COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONARY HEART DISEASE
    3.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONARY HEART DISEASE 有权
    用于治疗和预防冠状动脉疾病的组合物和方法

    公开(公告)号：US20140235607A1

    公开(公告)日：2014-08-21

    申请号：US14265862

    申请日：2014-04-30

    Applicant: Boston Heart Diagnostics Corporation

    Inventor： Ernst J. Schaefer ,  Eliana Polisecki

    IPC: A61K31/22 ,  C12Q1/68 ,  A61K31/397

    CPC classification number: C12Q1/6883 ,  A61K31/22 ,  A61K31/397 ,  C12Q1/6827 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172

    Abstract: The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.

    Abstract translation: 本发明涉及一种确定需要用他汀类药物治疗的个体的他汀类药物剂量的方法，包括从个体的核酸样品确定SLCO1B1基因型，所述基因型包括存在或不存在SLCO1B1-056多态性， 以及确定鉴定选自ApoE2，ApoE3，ApoE4及其任何组合的ApoE多态性的ApoE基因型或表型，其中鉴定SLCO1B1-056C多态性存在的SLCO1B1基因型与ApoE基因型的组合或 识别ApoE3 / 4或ApoE4 / 4基因型之一的表型表明他汀类药物的剂量。

    Driving patient compliance with therapy
    4.
    发明授权
    Driving patient compliance with therapy 有权

    公开(公告)号：US09828624B2

    公开(公告)日：2017-11-28

    申请号：US13949847

    申请日：2013-07-24

    Applicant: Boston Heart Diagnostics Corporation

    Inventor： Ernst J. Schaefer

    IPC: C12Q1/60 ,  G01N33/92 ,  G01N33/50 ,  A61K31/366 ,  A61K31/40 ,  A61K31/397

    CPC classification number: C12Q1/60 ,  A61K31/366 ,  A61K31/397 ,  A61K31/40 ,  G01N33/5008 ,  G01N33/92

    Abstract: Methods of the invention involve determining a patient's compliance with a cholesterol lowering therapy. In certain aspects, the invention provides methods that involve conducting a first assay to determine a cholesterol biomarker level in a first sample from a patient prior to the patient undergoing a cholesterol lowering therapy. The methods may also involve conducting a second assay to determine a cholesterol level in a second sample obtained from the patient after the patient has started undergoing a cholesterol lowering therapy. Additionally, the methods involve associating the cholesterol level and the cholesterol biomarker level in which the association allows for the determination of the patient's compliance with the cholesterol lowering therapy.

    DIABETES PANEL
    5.
    发明申请
    DIABETES PANEL 审中-公开
    糖尿病面板

    公开(公告)号：US20140120559A1

    公开(公告)日：2014-05-01

    申请号：US13662113

    申请日：2012-10-26

    Applicant: Boston Heart Diagnostics Corporation

    Inventor： Ernst J. Schaefer

    IPC: G01N33/566 ,  G01N27/26 ,  G01N30/02 ,  G01N33/53 ,  G01N33/66

    CPC classification number: G01N33/6893 ,  G01N33/66 ,  G01N33/74 ,  G01N33/92 ,  G01N2333/765 ,  G01N2405/02 ,  G01N2800/042 ,  G01N2800/50

    Abstract: The present invention generally relates to predicting the risk of developing diabetes in patients who currently do not have diabetes. The invention can involve obtaining a sample from a patient negative for diabetes, conducting an assay on the sample to obtain a level of a glycated albumin, and determining an elevated risk of developing a diabetic condition if the level exceeds a predetermined threshold.

    Abstract translation: 本发明一般涉及预测目前不具有糖尿病的患者发生糖尿病的风险。 本发明可以涉及从糖尿病阴性的患者获得样品，对样品进行测定以获得糖化白蛋白的水平，并且如果水平超过预定阈值，则确定发展糖尿病状态的风险升高。

    METHODS FOR DETERMINING WHETHER A PATIENT SHOULD BE ADMINISTERED A DRUG THAT INHIBITS CHOLESTEROL ABSORPTION
    6.
    发明申请
    METHODS FOR DETERMINING WHETHER A PATIENT SHOULD BE ADMINISTERED A DRUG THAT INHIBITS CHOLESTEROL ABSORPTION 审中-公开
    用于确定患者应该被给予的方法抑制胆固醇吸收的药物

    公开(公告)号：US20140088073A1

    公开(公告)日：2014-03-27

    申请号：US13950732

    申请日：2013-07-25

    Applicant: Boston Heart Diagnostics Corporation

    Inventor： Ernst J. Schaefer

    IPC: A61K31/397

    CPC classification number: A61K31/397 ,  A61K31/366 ,  A61K31/40 ,  C12Q1/60 ,  G01N33/502 ,  G01N33/92 ,  A61K2300/00

    Abstract: The invention generally relates to methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption. In certain aspects, methods of the invention involve obtaining a sample from a patient, conducting an assay on the sample to obtain a level of a cholesterol absorption marker, and comparing the level to a reference level, in which a level above the reference level indicates that the patient should be administered a drug that inhibits cholesterol absorption.

    Abstract translation: 本发明一般涉及用于确定患者是否应给予抑制胆固醇吸收的药物的方法。 在某些方面，本发明的方法包括从患者获得样品，对样品进行测定以获得胆固醇吸收标记的水平，并将该水平与参考水平进行比较，其中高于参考水平的水平表明 应该给予患者抑制胆固醇吸收的药物。

    INSULIN ACTIVITY MAP
    7.
    发明申请
    INSULIN ACTIVITY MAP 审中-公开

    公开(公告)号：US20180211722A1

    公开(公告)日：2018-07-26

    申请号：US15877726

    申请日：2018-01-23

    Applicant: BOSTON HEART DIAGNOSTICS CORPORATION

    Inventor： Michael Dansinger ,  Michael Riel-Mehan ,  Julia Maddalena

    IPC: G16H20/17 ,  G06F19/26 ,  G16H50/50

    CPC classification number: G16H20/17 ,  G16B45/00 ,  G16H20/10 ,  G16H50/30 ,  G16H50/50

    Abstract: An insulin activity map is a tool for assessing a patient's metabolic risk, designing a treatment plan, disseminating the information in a useful way to the patient, and encouraging the patient to remain on a treatment course. The insulin activity map combines a variety of inputs such as insulin sensitivity and insulin production to generate a patient-specific diagnosis and treatment assessment. The insulin activity map fills an important gap in prior art testing methods, providing diagnostic insights that improve clinician and patient understanding of the progression of diabetes, allows at-risk patients to more easily avoid developing diabetes, and helps diabetic and prediabetic patients manage and control the disease.

    Methods for determining LDL cholesterol treatment
    9.
    发明授权
    Methods for determining LDL cholesterol treatment 有权

    公开(公告)号：US09817001B2

    公开(公告)日：2017-11-14

    申请号：US13945436

    申请日：2013-07-18

    Applicant: Boston Heart Diagnostics Corporation

    Inventor： Bela F. Asztalos ,  Ernst J. Schaefer

    IPC: G01N33/92

    CPC classification number: G01N33/92 ,  G01N2800/52

    Abstract: Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises methods for devising a personalized treatment plan for a patient via the use of an extended CVD risk assessment panel measuring markers of cholesterol absorption and production and HDL subfractions. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers alone, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods.

Patent Agency Ranking